Source-grounded facts extracted from Neumora Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Neumora Therapeutics, Inc. announced a restructuring with charges of approximately $2 million (approximately 35%).
“On June 12, 2026, in connection with the discontinuation of development of navacaprant described below, the Company implemented a reduction in force of approximately 35%, which it expects to complete in the second and third quarters of 2026. The Company expects the reduction in force to result in an annualized cost savings of approximately $10 million, partially offset by one-time restructuring costs of approximately $2 million to be incurred in the second quarter of 2026.”
Material Agreements
Neumora Therapeutics, Inc. amended Third Amendment to the Loan and Security Agreement with K2 HealthVentures LLC (effective 2026-06-10).
“On June 10, 2026, Neumora Therapeutics, Inc. (the “Company” or “Neumora”) as borrower, entered into a Third Amendment to the Loan and Security Agreement (the “Third Amendment”), with K2 HealthVentures LLC as a lender, and the lenders party thereto from time to time (collectively, “Lenders”, and each, a “Lender”), and K2 HealthVentures LLC, as administrative agent for Lenders.”
Shareholder Votes
Neumora Therapeutics, Inc. shareholders approved Advisory vote on frequency of future advisory votes on executive compensation at the 2026-05-27 meeting.
“Proposal 4. The advisory vote on the frequency of future advisory votes on the compensation of the Company’s named executive officers. The results of the vote were as follows: For One Year For Two Years For Three Years Abstentions Broker Non-Votes 124,682,414 23,968 7,948,592 39,349 25,026,919”
Shareholder Votes
Neumora Therapeutics, Inc. shareholders approved Advisory vote on compensation of named executive officers at the 2026-05-27 meeting.
“Proposal 3. The advisory vote on the compensation of the Company’s named executive officers. The results of the vote were as follows: Votes For Votes Against Abstentions Broker Non-Votes 131,998,871 420,917 274,535 25,026,919”
Shareholder Votes
Neumora Therapeutics, Inc. shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-05-27 meeting.
“Proposal 2. The ratification of the selection by the audit committee of the board of directors of the Company (the “Board”) of Ernst & Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026. The results of the vote were as follows: Votes For Votes Against Abstentions 157,623,815 53,613 43,814”
Shareholder Votes
Neumora Therapeutics, Inc. shareholders approved Election of three Class III directors to hold office until the 2029 annual meeting at the 2026-05-27 meeting.
“Proposal 1. The election of three Class III directors to hold office until the 2029 annual meeting of stockholders and until their respective successor is elected and qualified or until their earlier death, resignation, disqualification or removal. The results of the vote were as follows: Nominee Votes For Votes Withheld Broker Non-Votes Paul L. Berns 126,617,746 6,076,577 25,026,919 Matthew Fust 125,242,046 7,452,277 25,026,919 David Piacquad 126,878,899 5,815,424 25,026,919”
Earnings Releases
Neumora Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: net income $53.5 million.
“compared to $18.8 million for the same period in 2025. The decrease was primarily attributable to lower personnel-related costs. • Net Loss: The Company reported a net loss of $53.5 million for the first quarter of 2026, as compared to $68.0 million for the same period in 2025.”
Earnings Releases
Neumora Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2025.
“On March 30, 2026, Neumora Therapeutics, Inc. (“Neumora” or the “Company”) announced its financial results for the fourth quarter and full year ended December 31, 2025.”
Equity Issuances
Neumora Therapeutics, Inc. issued 2,849,327 shares of common stock of common stock to K2 HealthVentures Equity Trust LLC for conversion of $2.5 million of principal amount at $0.8774 per share.
“of the term loans into shares of common stock of the Company. On November 17, 2025, the Company received a conversion notice from K2HV, pursuant to which K2HV elected to convert $2.5 million of principal amount of the term loan into common stock of the Company, at a conversion price of $0.8774 per share, in accordance with the Loan Agreement. On November 20, 2025,”
Listing & Compliance Notices
Neumora Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
“May 14, 2025, Neumora Therapeutics, Inc. (the “Company”) received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Global Select Market, as set forth in Listing Rule 5450(a)(1). In accordance with Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until November 10, 2025, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company’s common stock must meet or exceed $1.00”
Paul L. Berns was appointed as Chairman and Chief Executive Officer at Neumora Therapeutics, Inc..
“an Executive Employment Agreement, effective as of February 14, 2025, with Paul L. Berns, as the Company’s Chairman and Chief Executive Officer”
Henry Gosebruch departed as President and Chief Executive Officer at Neumora Therapeutics, Inc..
“the Company has entered into a Separation Agreement, dated February 14, 2025, with Henry Gosebruch, the Company’s former President and Chief Executive Officer”
Kaya Pai Panandiker departed as Chief Commercial Officer at Neumora Therapeutics, Inc..
“Kaya Pai Panandiker will depart the Company and no longer serve as Chief Commercial Officer.”
Carol Suh changed role as Chief Strategy Officer at Neumora Therapeutics, Inc..
“Carol Suh will transition from the role of Chief Operating Officer to Chief Strategy Officer”
Jason Duncan was appointed as Chief Legal and Administrative Officer at Neumora Therapeutics, Inc..
“Jason Duncan will serve as Chief Legal and Administrative Officer”
Michael Milligan was appointed as Chief Financial Officer at Neumora Therapeutics, Inc..
“Michael Milligan will serve as Chief Financial Officer in addition to his current role as principal accounting officer”
Bill Aurora changed role as Chief Operating and Development Officer at Neumora Therapeutics, Inc..
“Bill Aurora, Pharm.D. will transition from the role of Chief Strategy Officer to Chief Operating and Development Officer”
Joshua Pinto changed role as President at Neumora Therapeutics, Inc..
“Joshua Pinto, Ph.D. will transition from the role of Chief Financial Officer to President”
Henry Gosebruch departed as President, Chief Executive Officer at Neumora Therapeutics, Inc..
“Henry Gosebruch will depart the Company and no longer serve as President, Chief Executive Officer or a member of the Board.”
Paul L. Berns changed role as Chief Executive Officer and Chairman of the Board at Neumora Therapeutics, Inc..
“Paul L. Berns, the Company’s Co-Founder and Executive Chairman of its Board of Directors (the “Board”), will transition to the roles of Chief Executive Officer and Chairman of the Board”
Earnings Releases
Neumora Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: net income net loss of $53.7 million.
“announced its financial results for the first quarter ended March 31, 2024”
Earnings Releases
Neumora Therapeutics, Inc. reported financial results for fiscal year ended December 31, 2023.
“On March 7, 2024, Neumora Therapeutics, Inc. (“Neumora” or the “Company”) announced its financial results for the fourth quarter and full year ended December 31, 2023.”
Earnings Releases
Neumora Therapeutics, Inc. reported the third quarter ended September 30, 2023 results: net income $53.0 million.
“The Company reported a net loss of $53.0 million for the third quarter of 2023”
Governance Changes
Neumora Therapeutics, Inc.: Amended and restated bylaws effective upon closing of IPO, including provisions for advance notice, written consent prohibition, director removal, classified board, and forum selection (effective 2023-09-19).
“On September 19, 2023, Neumora Therapeutics, Inc.’s (the “Company”) amended and restated certificate of incorporation (the “Certificate of Incorporation”), filed with the Secretary of State of the State of Delaware on September 19, 2023, and its amended and restated bylaws (the “Bylaws”) became effective in connection with the closing of the initial public offering of shares of the Company’s common stock.”
Governance Changes
Neumora Therapeutics, Inc.: Amended and restated certificate of incorporation effective upon closing of IPO, including changes to authorized shares, preferred stock, director election, stockholder action, and forum selection provisions (effective 2023-09-19).
“On September 19, 2023, Neumora Therapeutics, Inc.’s (the “Company”) amended and restated certificate of incorporation (the “Certificate of Incorporation”), filed with the Secretary of State of the State of Delaware on September 19, 2023, and its amended and restated bylaws (the “Bylaws”) became effective in connection with the closing of the initial public offering of shares of the Company’s common stock.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.